Log in to save to my catalogue

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral can...

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral can...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bc8a63ae25d34d01a0aaf495a184cd65

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

About this item

Full title

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer Communications, 2021-03, Vol.41 (3), p.279-283

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Due to the limited sample size of the clinical N2 group, our retrospective subgroup analyses were not sufficient to guide further treatment plan until further demonstrated by convincing studies. Besides clinical indicators, we also focused on the predictive effect of pathological response after induction chemotherapy. The pCR rate was consistent wi...

Alternative Titles

Full title

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_bc8a63ae25d34d01a0aaf495a184cd65

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bc8a63ae25d34d01a0aaf495a184cd65

Other Identifiers

ISSN

2523-3548

E-ISSN

2523-3548

DOI

10.1002/cac2.12136

How to access this item